Logo

Peter MacCallum Cancer Center Researchers to Use Agilent CGH Array Technology in Study

Apr 15, 2005

NEW YORK, April 15 (GenomeWeb News) - Agilent Technologies today announced that researchers at Peter MacCallum Cancer Center of Melbourne, Australia, will use its comparative genomic-hybridization microarray products in a three-year cancer study.

 

The researchers will use the human CGH arrays to study mesothelioma, a cancer found in the lining of the chest, the abdominal cavity and around the heart, usually caused by exposure to asbestos.

 

Financial details were not disclosed.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.